Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer

References

• Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999;91:869–874.
   PubMed Web of Science ®Google Scholar
• Riisbro R, Christensen IJ, Nielsen HJ, et al. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers. 2005;20:93–102.
   Web of Science ®Google Scholar
• Fidan E, Mentese A, Ozdemir F, et al. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol. 2013;30:540–549.
   PubMed Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38:1418–1428.
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjanen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011;270:32–40.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Koch A, Seidler S, et al. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012;32:500–509.
   PubMed Web of Science ®Google Scholar
• Andersen ES, Ruhwald M, Moessner B, et al. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis. 2011;30:761–766.
   PubMed Web of Science ®Google Scholar
• Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 2010;10:2–3.
   PubMed Web of Science ®Google Scholar
• Sorio C, Mafficini A, Furlan F, et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer. 2011;11:44–48.
   PubMed Web of Science ®Google Scholar
• Loosen SH, Tacke F, Puthe N, et al. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. Carcinogenesis. 2019;40:947–955.
   PubMed Web of Science ®Google Scholar
• Nikkola A, Aittoniemi J, Huttunen R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor predicts the severity of acute alcohol pancreatitis. Pancreas. 2017;46:77–82.
   PubMed Web of Science ®Google Scholar
• Aronen A, Aittoniemi J, Huttunen R, et al. Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis. Eur J Intern Med. 2019;64:72–75.
   PubMed Web of Science ®Google Scholar
• Nordback I, Pelli H, Lappalainen-Lehto R, et al. The recurrence of acute alcohol-associated pancreatitis can be reduced: a randomized controlled trial. Gastroenterology. 2009;136:848–855.
   PubMed Web of Science ®Google Scholar
• Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388–395.
   PubMed Web of Science ®Google Scholar
• Nojgaard C, Becker U, Matzen P, et al. Progression from acute to chronic pancreatitis: prognostic factors, mortality, and natural course. Pancreas. 2011;40:1195–1200.
   PubMed Web of Science ®Google Scholar
• Habtezion A. Inflammation in acute and chronic pancreatitis. Curr Opin Gastroenterol. 2015;31:395–399.
   PubMed Web of Science ®Google Scholar
• Haupt TH, Kallemose T, Ladelund S, et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 2014;9:91–100.
   PubMedGoogle Scholar
• Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–465.
   PubMed Web of Science ®Google Scholar
• Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957–963.
   PubMed Web of Science ®Google Scholar
• Wingren C, Sandstrom A, Segersvard R, et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 2012;72:2481–2490.
   PubMed Web of Science ®Google Scholar
• Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53–55.
   PubMed Web of Science ®Google Scholar
• Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP. 2010;11:203–212.
   PubMedGoogle Scholar
• Fry LC, Monkemuller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883–890.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441–447.
   PubMed Web of Science ®Google Scholar
• Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442–446.
   PubMed Web of Science ®Google Scholar
• Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198:333–339.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501–5503.
   PubMed Web of Science ®Google Scholar
• Murakami T, Hiroshima Y, Matsuyama R, et al. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019;3:130–137.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wolfgang CL, Zheng L. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel). 2018;10:39.
   Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–444.
   PubMed Web of Science ®Google Scholar
• Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–172.
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308.
   PubMed Web of Science ®Google Scholar